Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 34

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 34
---
 of, our product candidates; |

| • | our ability to obtain accelerated approval for current and future product candidates from the U.S. Food and Drug Administration, or FDA, the European Commission, or other comparable regulatory authorities in other jurisdictions; |

| • | our expectations regarding business disruptions affecting the initiation, patient enrollment, clinical trial site monitoring, development and operation of our current and proposed clinical trials, including as a result of a public health emergency or other global and macroeconomic factors, such as the war in Ukraine, the conflict in the Middle East, global geopolitical tensions, supply chain disruptions, and changes in interest rates and inflation; |

| • | our business strategies and goals; |

| • | our plans to collaborate, or statements regarding our current collaborations, and our ability to find future partners and collaborators; |

| • | the performance of our third-party suppliers and manufacturers; |

| • | our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for our products and product candidates and our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others; |

| • | our expectations regarding competition with respect to KIMMTRAK or any of our current or future product candidates, as well as innovations by current and future competitors in our industry; |

| • | our expectations regarding regulatory developments in the United States, United Kingdom and other countries, including potential changes in healthcare laws and regulations; |

| • | our financial performance and our ability to effectively manage our anticipated growth; |

| • | our ability to identify, recruit and retain qualified employees, including key commercial or management personnel; and |

| • | whether we are classified as a PFIC for current and future periods. |

You should refer to the important factors in the cautionary statements included in this prospectus supplement, the accompanying base prospectus and in the other documents incorporated herein and therein for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in and incorporated by reference into this prospectus supplement and the accompanying base prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives